CBD and THC are two of the most commonly discussed compounds found in the cannabis plant. If you are researching medicinal cannabis in Australia, you may come across these terms frequently during discussions about treatment options and clinical assessments.
While CBD and THC come from the same plant, they have different characteristics and may be considered differently by healthcare practitioners. Understanding the differences between CBD and THC can help patients have more informed conversations with their healthcare team.
This article provides a general overview of CBD and THC, how they differ, and what may be discussed during a medicinal cannabis consultation.
Cannabinoids are naturally occurring compounds found in the cannabis plant. Researchers have identified more than 100 different cannabinoids, although CBD (cannabidiol) and THC (tetrahydrocannabinol) are among the most widely known.
Cannabinoids interact with the body's endocannabinoid system, which is a complex system involved in maintaining balance across various physiological processes.
Research into cannabinoids continues to evolve, and healthcare practitioners consider available evidence, patient history, and individual circumstances when assessing treatment options.
CBD stands for cannabidiol.
It is a cannabinoid that does not generally produce the intoxicating effects commonly associated with cannabis.
CBD-containing medicinal cannabis products may be discussed by healthcare practitioners as part of a broader clinical assessment where appropriate.
Some characteristics commonly associated with CBD include:
Non-intoxicating in typical circumstances
Derived from the cannabis plant
Available in a range of approved medicinal cannabis formulations
Subject to Australian regulatory requirements
CBD products can vary significantly in composition and formulation. Healthcare practitioners assess individual circumstances before determining whether any treatment option may be suitable.
THC stands for tetrahydrocannabinol.
THC is the primary cannabinoid associated with the psychoactive effects of cannabis. Psychoactive effects refer to changes in perception, mood, awareness, or cognition.
THC-containing medicinal cannabis products may also be considered during clinical assessments where appropriate.
Characteristics commonly associated with THC include:
Psychoactive effects may occur
Derived from the cannabis plant
Available in regulated medicinal cannabis formulations
May affect driving ability and other activities requiring concentration
Because THC may affect alertness and cognitive function, healthcare practitioners carefully consider patient-specific factors before discussing THC-containing treatment options.
Full Name
Psychoactive Effects
Source
Regulation
Clinical Assessment Required
Cannabidiol
Generally not intoxicating
Cannabis plant
Subject to Australian regulations
Yes
Tetrahydrocannabinol
May produce psychoactive effects
Cannabis plant
Subject to Australian regulations
Yes
Some medicinal cannabis products contain a combination of CBD and THC.
The ratio between these cannabinoids can vary depending on the formulation prescribed by a healthcare practitioner.
During a consultation, a registered practitioner may consider factors such as:
Medical history
Current medications
Symptoms being discussed
Previous treatment experiences
Individual health circumstances
Safety considerations
Treatment decisions are based on clinical assessment rather than a single cannabinoid alone.
Medicinal cannabis products can contain:
CBD only
THC only
A combination of CBD and THC
These products may be available in different formats, including:
Oils
Capsules
Oral liquids
Other approved medicinal formulations
The specific product type discussed during a consultation depends on individual circumstances and clinical judgement.
Healthcare practitioners determine whether any medicinal cannabis product may be appropriate based on a thorough assessment.
Medicinal cannabis products in Australia are regulated.
Access generally occurs through pathways that involve assessment by an authorised healthcare practitioner.
Practitioners consider:
Medical history
Current treatments
Potential risks
Potential interactions with other medications
Relevant clinical information
Not all patients are suitable candidates for medicinal cannabis, and treatment decisions are made on a case-by-case basis.
Driving considerations are an important topic during medicinal cannabis consultations.
Australian driving laws vary between states and territories, and patients should discuss driving-related considerations with their healthcare practitioner.
In particular, THC may have implications for driving and roadside drug testing.
Healthcare practitioners can provide information relevant to a patient's individual circumstances and local regulations.
Patients should never assume that a medicinal cannabis prescription automatically permits driving.
A healthcare practitioner may discuss topics such as:
Current health concerns
Previous treatments
Current medications
Medical history
Lifestyle considerations
Potential treatment pathways
Safety considerations
Monitoring requirements
The purpose of the consultation is to assess the patient's overall clinical situation and determine whether any treatment option may be appropriate.
CBD and THC are only part of a broader clinical conversation.
Healthcare practitioners do not make decisions based solely on whether a product contains CBD or THC. Instead, they consider the complete clinical picture, including:
Individual circumstances
Existing medical conditions
Medication history
Treatment goals
Safety considerations
This approach helps ensure that treatment decisions are patient-centred and based on professional clinical judgement.
No. CBD (cannabidiol) and THC (tetrahydrocannabinol) are different cannabinoids found in the cannabis plant and have different characteristics.
CBD is generally considered non-intoxicating and is not typically associated with the psychoactive effects commonly linked to THC.
Yes. Some medicinal cannabis products contain both cannabinoids in varying ratios.
A qualified healthcare practitioner determines whether a treatment option may be appropriate based on a clinical assessment and individual circumstances.
No. Products can differ in cannabinoid content, formulation, and other characteristics.
Treatment decisions involving medicinal cannabis should be made in consultation with a registered healthcare practitioner who can assess individual circumstances.
CBD and THC are two well-known cannabinoids found in the cannabis plant, but they have different characteristics and considerations. CBD is generally regarded as non-intoxicating, while THC may produce psychoactive effects and has additional considerations such as driving implications.
During a medicinal cannabis consultation, healthcare practitioners assess the broader clinical picture rather than focusing on a single cannabinoid. Any discussion about CBD, THC, or medicinal cannabis products should occur as part of a professional clinical assessment that takes into account individual circumstances, medical history, and treatment needs.